| 2.05 0.02 (0.99%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.92 | 1-year : | 3.57 |
| Resists | First : | 2.5 | Second : | 3.05 |
| Pivot price | 2.03  |
|||
| Supports | First : | 1.61 | Second : | 1.33 |
| MAs | MA(5) : | 2  |
MA(20) : | 2.04 |
| MA(100) : | 2.07 |
MA(250) : | 1.8 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 41.6 |
D(3) : | 30.8 |
| RSI | RSI(14): 46.1 |
|||
| 52-week | High : | 3.05 | Low : | 0.62 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MIST ] has closed below upper band by 46.1%. Bollinger Bands are 47.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.11 - 2.12 | 2.12 - 2.13 |
| Low: | 1.95 - 1.97 | 1.97 - 1.98 |
| Close: | 2.03 - 2.05 | 2.05 - 2.07 |
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Thu, 15 Jan 2026
Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense (MIST) - Seeking Alpha
Tue, 13 Jan 2026
Milestone Pharmaceuticals Completes Royalty Interest Sale - TradingView — Track All Markets
Fri, 09 Jan 2026
Insider Sell: Joseph Oliveto Sells 43,500 Shares of Milestone Ph - GuruFocus
Tue, 06 Jan 2026
Europe reviews first nose-spray patients could use for sudden PSVT - Stock Titan
Tue, 06 Jan 2026
Milestone Pharmaceuticals Announces Acceptance of Marketing - GlobeNewswire
Wed, 24 Dec 2025
Milestone Pharmaceuticals’ Stock Surges as Cardamyst Receives FDA Approval - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 85 (M) |
| Shares Float | 77 (M) |
| Held by Insiders | 3.3 (%) |
| Held by Institutions | 50.6 (%) |
| Shares Short | 8,220 (K) |
| Shares Short P.Month | 4,950 (K) |
| EPS | -0.8 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.2 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -42 % |
| Return on Equity (ttm) | -260.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -43 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -2.6 |
| PEG Ratio | 0 |
| Price to Book value | 10.25 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|